Our study was conducted to optimise a peptide stimulation and an intracellular cytokine staining protocol, alongside Bio-Plex supernatant analysis, for use in patients who had previously contracted SARS-CoV-2 or received vaccination against this virus in a clinical laboratory setting. Peripheral Blood Mononuclear Cell extraction and cryopreservation allowed for cells to be stored long term and enhanced logistical processing of samples. Viability and functionality of cells were analysed by flow cytometric methodology using viability staining monoclonal antibodies conjugated to fluorochromes. Antibiotics and Benzonase Nuclease did not impact lymphocyte viability and so cell culture conditions were optimised in terms of retaining viability and functionality. Optimisation of peptide stimulation with Influenza and SARS-CoV-2 peptide pools was conducted through stimulation experiments assessing peptide concentration, peptide stimulation time and enrichment studies to increase precursor frequency. Cytokine output was measured by flow cytometry and Bio-Plex methodologies, with positive cytokine readings predominantly detected in the cell culture supernatant. Analysis of both intracellular and extracellular compartments allowed for detection of cytokines and established the retained cellular functionality post cryopreservation. These results also indicated that our peptide stimulation method can generate antigen-specific T lymphocytes upon exposure to SARS-CoV-2 peptide pools. Moreover, the measurement of specific cytokines could be applied to an array of conditions, such as chronic inflammatory diseases, but to also offer an alternative method of measuring vaccine responses. This platform is easily adaptable and can remain relevant alongside changing vaccine composition, thus ensuring its applicability to future vaccination programmes.
Background: The difference in the immune response to severe acute respiratory syndrome coro-navirus 2 (SARS-CoV-2) in patients with mild versus severe disease remains poorly understood. Recent scientific advances have recognised the vital role of both B cells and T cells; however, many questions remain unanswered, particularly for T cell responses. T cells are essential for helping the generation of SARS-CoV-2 antibody responses but have also been recognised in their own right as a major factor influencing COVID-19 disease outcomes. The examination of T cell receptor (TCR) family differences over a 12-month period in patients with varying COVID-19 disease severity is crucial for understanding T cell responses to SARS-CoV-2. Methods: We applied a machine learning approach to analyse TCR vb family responses in COVID-19 patients (n = 151) across multiple timepoints and disease severities alongside SARS-CoV-2 infection-naïve (healthy control) individ-uals (n = 62). Results: Blood samples from hospital in-patients with moderate, severe, or critical disease could be classified with an accuracy of 94%. Furthermore, we identified significant variances in TCR vb family specificities between disease and control subgroups. Conclusions: Our findings suggest advantageous and disadvantageous TCR repertoire patterns in relation to disease severity. Following validation in larger cohorts, our methodology may be useful in detecting protective immunity and the assessment of long-term outcomes, particularly as we begin to unravel the immunological mechanisms leading to post-COVID complications.
Background/Objective: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with clinical and serological heterogeneity. Current laboratory assays show variable performance for disease detection and risk stratification, resulting in diagnostic delays exceeding six years. There is an unmet need for improved diagnostic and monitoring tools. This study examines the clinical application of Fourier-transform infrared (FTIR) spectroscopy as a rapid, label-free technique for classifying SLE and other connective tissue diseases (CTDs). Methods: Serum samples from patients with SLE, Sjögren’s syndrome (SS), undifferentiated CTD (UCTD), and healthy controls (HCs) were analysed by FTIR spectroscopy followed by genetic algorithm–linear discriminant analysis (GA-LDA) modelling at two time points: baseline and six-month follow-up. Results: FTIR spectroscopy reliably differentiated CTDs from HCs with accuracies of 94.2% (inclusive of all time points), 99.3% at baseline, and 97.5% at follow-up. SLE patients were successfully separated from disease controls, achieving classification accuracies of 100% at baseline and 97.4% at follow-up. Subgroup analysis also demonstrated good classification accuracies for SLE (81.7%), SS (82.9%), and UCTD (86.1%), with discriminatory spectral features aligning with disease-related biochemical assignments. Notably, wavenumbers associated with proteins, carbohydrates, lipids, and DNA showed increased absorbance intensities in CTD patients, potentially reflecting immune dysregulation and metabolic changes. Conclusions: FTIR spectroscopy can reliably distinguish patients with SLE from both other CTDs and healthy individuals and may offer greater diagnostic utility than conventional serological testing. Identification of longitudinal variations in wavenumber biomarkers further supports the clinical potential of this technique and suggests possible future applications in therapeutic monitoring and risk stratification within rheumatological autoimmune disorders.